NO3066097T3 - - Google Patents
Info
- Publication number
- NO3066097T3 NO3066097T3 NO14793565A NO14793565A NO3066097T3 NO 3066097 T3 NO3066097 T3 NO 3066097T3 NO 14793565 A NO14793565 A NO 14793565A NO 14793565 A NO14793565 A NO 14793565A NO 3066097 T3 NO3066097 T3 NO 3066097T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13192177 | 2013-11-08 | ||
PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
EP14793565.4A EP3066097B1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
Publication Number | Publication Date |
---|---|
NO3066097T3 true NO3066097T3 (ru) | 2018-01-13 |
Family
ID=49552231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO14793565A NO3066097T3 (ru) | 2013-11-08 | 2014-11-05 |
Country Status (33)
Country | Link |
---|---|
US (1) | US9926305B2 (ru) |
EP (1) | EP3066097B1 (ru) |
JP (1) | JP6446051B2 (ru) |
KR (1) | KR102351418B1 (ru) |
CN (1) | CN105658647B (ru) |
AP (1) | AP2016009181A0 (ru) |
AU (1) | AU2014345599B2 (ru) |
BR (1) | BR112016010253A8 (ru) |
CA (1) | CA2929780C (ru) |
CL (1) | CL2016001096A1 (ru) |
CY (1) | CY1119520T1 (ru) |
DK (1) | DK3066097T3 (ru) |
EA (1) | EA033132B1 (ru) |
ES (1) | ES2645480T3 (ru) |
HK (1) | HK1222171A1 (ru) |
HR (1) | HRP20171603T1 (ru) |
HU (1) | HUE035021T2 (ru) |
IL (1) | IL245407B (ru) |
LT (1) | LT3066097T (ru) |
MA (1) | MA39020A1 (ru) |
ME (1) | ME02907B (ru) |
MX (1) | MX366848B (ru) |
MY (1) | MY190108A (ru) |
NO (1) | NO3066097T3 (ru) |
PH (1) | PH12016500853B1 (ru) |
PL (1) | PL3066097T3 (ru) |
PT (1) | PT3066097T (ru) |
RS (1) | RS56509B1 (ru) |
SA (1) | SA516371082B1 (ru) |
SI (1) | SI3066097T1 (ru) |
TN (1) | TN2016000170A1 (ru) |
UA (1) | UA117686C2 (ru) |
WO (1) | WO2015067652A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
WO2018197333A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
WO2022135502A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
WO2023194222A1 (en) * | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019068A1 (en) * | 2000-10-19 | 2004-01-29 | Mizuo Miyazaki | Novel remedies or preventives for angiostenosis |
AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
CN104168779A (zh) * | 2012-03-05 | 2014-11-26 | 格拉图克技术私人有限公司 | 膳食补充剂 |
UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
WO2015067651A1 (de) * | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile als chymase inhibitoren |
-
2014
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de active Application Filing
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active IP Right Grant
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
- 2016-08-30 HK HK16110283.7A patent/HK1222171A1/zh unknown
-
2017
- 2017-10-19 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown